title: Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
authors.affiliation: Hunton & Williams LLP, USA.
authors.forename: Esther H
authors.initials: EH
authors.lastname: Steinhauer
mesh_terms: D016363:Antitrust Laws; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D004465:Economic Competition / Q000331:legislation & jurisprudence; D005607:Fraud / Q000331:legislation & jurisprudence; D006801:Humans; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D011356:Product Labeling / Q000331:legislation & jurisprudence; D014481:United States; D014486:United States Food and Drug Administration